Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2013 1
2016 4
2017 1
2018 2
2019 1
2020 1
2021 2
2022 2
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Holmes FA, Moy B, Delaloge S, Chia SKL, Ejlertsen B, Mansi J, Iwata H, Gnant M, Buyse M, Barrios CH, Silovski T, Šeparović R, Bashford A, Zotano AG, Denduluri N, Patt D, Gokmen E, Gore I, Smith JW 2nd, Loibl S, Masuda N, Tomašević Z, Petráková K, DiPrimeo D, Wong A, Martin M, Chan A; ExteNET Study Group. Holmes FA, et al. Among authors: silovski t. Eur J Cancer. 2023 May;184:48-59. doi: 10.1016/j.ejca.2023.02.002. Epub 2023 Feb 10. Eur J Cancer. 2023. PMID: 36898233 Free article. Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group. Chan A, et al. Among authors: silovski t. Lancet Oncol. 2016 Mar;17(3):367-377. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10. Lancet Oncol. 2016. PMID: 26874901 Clinical Trial.
Expert Discussion: ASCO 2022.
Balic M, Wimmer K, Suppan C, Silovski T, Brunner C. Balic M, et al. Among authors: silovski t. Breast Care (Basel). 2022 Aug;17(4):430-436. doi: 10.1159/000525966. Epub 2022 Jul 8. Breast Care (Basel). 2022. PMID: 36156916 Free PMC article. No abstract available.
OXALIPLATIN INDUCED PULMONARY FIBROSIS: A CASE REPORT.
Pavlović M, Šeparović R, Silovski T, Tečić Vuger A, Jurić A. Pavlović M, et al. Among authors: silovski t. Acta Clin Croat. 2020 Dec;59(4):761-764. doi: 10.20471/acc.2020.59.04.25. Acta Clin Croat. 2020. PMID: 34285449 Free PMC article.
Rapid hair depigmentation in patient treated with pazopanib.
Šeparović R, Pavlović M, Silovski T, Tečić Vuger A. Šeparović R, et al. Among authors: silovski t. BMJ Case Rep. 2018 Aug 23;2018:bcr2018224209. doi: 10.1136/bcr-2018-224209. BMJ Case Rep. 2018. PMID: 30139781 Free PMC article.
22 results